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T1 Mapping in Cardiac Amyloidosis
Can We Get There From Here?*
Frederick L. Ruberg, MD
Boston, Massachusettsm
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aThe accurate identification of cardiac involvement
in systemic light-chain (AL) amyloidosis is a critical
aspect of clinical care. Mortality from cardiovascular
causes is the most common cause of death in
patients with AL amyloidosis, and those with car-
diac involvement, seen in approximately 50% of
patients with AL disease, are at the highest risk (1).
Recognition of cardiac involvement informs clinical
decisions regarding antiplasma cell therapy and
heart failure management (2).
See page 488
In the latter half of the 20th century, cardiac
involvement could not be reliably demonstrated
without invasive endomyocardial biopsy (3). Con-
temporary diagnostic algorithms that incorporate
cardiac specific biomarkers, such as troponin or
B-type natriuretic peptide, and modern echocardio-
graphic techniques have essentially obviated the
need for cardiac biopsy in the vast majority of cases
(4). However, even with these sensitive noninvasive
tests, there can remain situations of clinical uncer-
tainty as to whether cardiac involvement is present.
Cardiac magnetic resonance (CMR), unlike the
tests described in the preceding text, can identify
cardiac amyloidosis because of its capacity to afford
tissue characterization. Myocardial amyloid deposi-
tion results in interstitial space expansion, which, in
turn, can be visualized by late gadolinium enhance-
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sity School of Medicine and Boston Medical Center, Boston,a
Massachusetts. Dr. Ruberg has reported that he has no relationships
relevant to the contents of this paper to disclose.ent (LGE) imaging (5). Furthermore, light
hains also result in myocyte death and a degree of
eactive fibrosis that contribute to interstitial space
xpansion and LGE. Multiple studies have vali-
ated LGE CMR as a means to identify cardiac
nvolvement in AL disease with a combined sensi-
ivity that approaches 85% to 90% (5–9). However,
GE imaging has a number of limitations in
myloid disease. First, gadolinium contrast is re-
uired and cannot be administered to patients with
evere renal impairment. Second, the patterns of
GE seen in amyloidosis are by no means uniform
nd are quite variable, leading to confusion in
nterpretation (7). Finally, LGE can be difficult to
uantitate in cardiac amyloidosis wherein the inten-
ity of signal is variable, its distribution patchy, and
requently is noncontiguous.
In this issue of iJACC, Karamitsos et al. (10)
ircumvent the previously described shortcomings
f LGE CMR by using noncontrast, quantitative,
1 mapping to identify cardiac amyloid involve-
ent in systemic AL disease (10). Studies of T1
apping have expanded over the past few years,
ith data reported for a variety of nonischemic
rocesses, including amyloidosis (11,12).
In the current study, the investigators recruited
3 patients with biopsy-proven, systemic AL amy-
oidosis and grouped them into 3 categories by
chocardiographic wall thickness measures, dia-
tolic functional assessment, and biomarker data: no
ardiac involvement (26% of the cohort), possible
nvolvement (21%), and definite involvement
53%). Comparison cohorts of healthy controls and
atients with aortic stenosis matched by wall thick-
ess to the amyloid patients were also recruited.
ine CMR followed by pre-contrast T1 mapping
nd LGE post-contrast was performed at 1.5T with
global, mean T1 value calculated.
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499As predicted, patients with definite involvement
had greater myocardial mass and higher estimated
filling pressures. Karamitsos et al. (10) found that
T1 values were highest among patients with defi-
nite cardiac amyloidosis (mean 1,140  61 ms) as
compared to either healthy controls (958  20 ms)
r those with aortic stenosis (979  51 ms). Next,
hen stratified by the noninvasive pre-CMR group
ssignment, there was a stepwise increase in T1.
sing receiver-operating characteristic (ROC)
nalysis, a threshold noncontrast T1 value of 1,020
s yielded 92% accuracy for identification of either
ossible or definite cardiac involvement. Correla-
ions between T1 values and indices of morphology,
ystolic, and diastolic function were observed.
Because endomyocardial biopsies were only per-
ormed in 8% of the patients, we do not know
hich patients definitely had cardiac amyloidosis,
ut the LGE data help elucidate the pre-test group
ssignments. In the definite group, nearly all (96%)
ad either LGE or an abnormal myocardium to
lood pool signal suppression pattern indicative of
iffuse cardiac infiltration. Conversely, in the no
myloid pre-test group, none of the patients had
GE or an abnormal suppression pattern. How-
ver, in the possible cardiac amyloid group, approx-
mately 50% had LGE or an abnormal suppression
attern. Karamitsos et al. (10) suggest that some of
hose patients without LGE may also have cardiac
myloidosis, even with normal biomarkers and wall
hickness, by noting that T1 values above the ROC
hreshold were observed in 4 of 6 patients without
GE. While interesting to consider, this observa-
ion is unlikely to be of clinical importance given
he ample data that now exist relating normal
iomarkers to favorable clinical outcomes (13).
The ROC analysis allocated positive cases from
oth the definite or possible groups, which, there-
ore, likely included some patients in the possible
roup without cardiac involvement. Thus, the re-
orted accuracy of 92% may be an over-estimate of
ho truly has cardiac involvement. It is interesting
o note that this accuracy is not that dissimilar from
hat reported for LGE CMR.
More careful review of the T1 data as classified
y subgrouping reveals minimal overlap between
he definite and no cardiac involvement groups,
espite the finding that mean–T1 among patients
ith no cardiac involvement was nonetheless in-
reased compared to normal controls.
What appears most intriguing is the observed
ifference in T1 between patients with definite
ardiac amyloidosis and aortic stenosis, despite cimilar left ventricle mass, and LGE noted in 32%
f the aortic stenosis patients. Histologically, we
an presume that the aortic stenosis patients had
ome degree of interstitial fibrosis that resulted in
he LGE, yet the LGE images alone may not have
een sufficient to differentiate the 2 entities. Here is
here pre-contrast T1 mapping might be most
elpful—to differentiate between wall thickness
ncrease due to amyloidosis versus hypertrophy and
nterstitial fibrosis. Karamitsos et al. (10) astutely
omment upon this, but also caution that as wall
hickness and fibrosis increase, noncontrast T1
alues may also increase. It is more challenging to
ake a distinction between interstitial space expan-
ion from amyloidosis versus fibrosis in post-
ontrast studies. In a recent study of cardiac amy-
oidosis, post-contrast T1 mapping was utilized to
etermine the gadolinium partition coefficient and
hereby derive a measurement of the extracellular
olume fraction (14). Extracellular volume fraction
as markedly increased in amyloidosis, and thus the
agnitude of increase may be important.
How is this technique useful to the clinician? Its
reatest merit is that it is a noncontrast, quantitative
easurement that is relatively simply to perform
nd analyze, has minimal subjectivity, and is highly
eproducible. In general, T1 mapping is sensitive to
lobal changes in myocardial tissue, and, therefore,
ypothetically may confer an advantage over LGE
hen applied to diffuse infiltrative processes such as
myloidosis. Performed serially, it may afford a
ore accurate means to follow response to treat-
ent and changes in myocardial amyloid burden.
It is important to note that these data should be
onsidered only to apply to patients with systemic
L disease, and not to those with transthyretin
ardiac amyloidosis. Patients with wild-type tran-
thyretin disease tend to have considerably thicker
earts (15) and would predictably have even higher
oncontrast T1 values. Hypertrophic cardiomyop-
thy would be another important comparator, as its
maging characteristics also overlap with cardiac
myloidosis. Notably, a report of noncontrast T1
apping in hypertrophic cardiomyopathy by these
nvestigators is unfortunately not comparable to the
resent study as it was performed at 3.0-T (16).
Finally, there are a number of pulse sequences
hat can be used to perform T1 mapping with
ifferent reproducibility and accuracy. The tech-
ique employed here, the shortened modified look-
ocker inversion recovery (shMOLLI) sequence, is
ess subject to artifacts from respiratory motion, but
urrently has limited availability (17).
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500In summary, T1 mapping techniques such as
that reported by Karamitsos et al. (10) have great
promise to shape our approach to the manage-
ment of patients with cardiac amyloidosis. Future
studies of T1 mapping protocols utilizing larger
cohorts, that include other amyloid precursor
protein types, and that correlate imaging charac-
teristics to clinical outcomes, is warranted. How-7. Syed IS, Glockner JF, Feng D, et al.
Role of cardiac magnetic resonance
1
1
1
1
chain amyloidosis:
diagnosis, risk-stachieve widespread clinical application, there
must be standardization and simplification of
sequences and post-processing products.
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